ExonHit SpliceArrays to be marketed by Agilent

New York, May 31 - ExonHit Therapeutics said it has entered into a marketing alliance under which Agilent Technologies, Inc. will market and sell nine of its human and mouse SpliceArrays as commercial products.

These SpliceArrays include: GPCR, ion channel, nuclear receptors and apoptosis pathways.

"Splice variant analysis is the next natural development in gene expression technology, and we see it as holding important value for the biomedical research community," Fran Dinuzzo, Agilent vice president and general manager, Integrated Biology Solutions, said in a news release.

"SpliceArray technology also complements our portfolio of microarray-based research tools and the ExonHit team has proven to be a source of well-designed solutions."

ExonHit's SpliceArrays originally became available through Agilent in August 2005 and the new agreement expands that collaboration.

ExonHit is a Paris, France-based company specializing in analysis of alternative RNA splicing. Agilent is a Palo Alto, Calif., measurement and analysis company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.